Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 109

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 109
---
 2022 convertible senior notes— — (156,960)Repayment of 2024 convertible senior notes(8,641)— (192,609)Repayment of 2025 convertible senior notes(190,994)— — Repayment of Term loan B facility— (296,875)(78,125)Repayment of Term loan A facility(11,250)(33,437)— Purchase of capped call transactions(26,709)— — Debt extinguishment costs— (5,750)— Payment of debt issuance and financing costs(9,350)(1,163)(1,175)Net cash provided by (used in) financing activities17,363 (183,031)(401,528)Net increase (decrease) in cash and cash equivalents123,476 49,159 (481,439)Cash and cash equivalents, beginning of year153,298 104,139 585,578 Cash and cash equivalents, end of year$276,774 $153,298 $104,139 See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-9

PACIRA BIOSCIENCES, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)(In thousands)Year Ended December 31,202420232022Supplemental cash flow information:   Cash paid for interest$15,418 $27,635 $33,295 Cash paid for income taxes, net of refunds$11,021 $4,366 $7,398 Non-cash investing and financing activities:   Issuance of common stock from conversion of 2022 convertible senior notes$— $— $3,040 Fixed assets included in accounts payable and accrued liabilities$5,565 $1,982 $5,888 Excise tax on share repurchases included in accrued liabilities$121 $— $— 

See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-10